Schedule 13G ownership disclosure
KalVista Pharmaceuticals Inc
Common Stock, par value $0.001 per share · CUSIP: 483497103
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- TANG CAPITAL MANAGEMENT, LLC
Shares: 4,941,798.00 · Class: 9.9%
- KEVIN TANG
Shares: 4,941,798.00 · Class: 9.9%
- TANG CAPITAL PARTNERS, LP
Shares: 3,279,836.00 · Class: 6.6%
- TANG CAPITAL PARTNERS INTERNATIONAL, LP
Shares: 706,962.00 · Class: 1.4%
- TANG CAPITAL PARTNERS III, INC
Shares: 855,000.00 · Class: 1.7%
- TANG CAPITAL PARTNERS IV, INC
Shares: 100,000.00 · Class: 0.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001214659-25-007877
- Form type
- SCHEDULE 13G/A
- Filer
- KalVista Pharmaceuticals, Inc.
- CIK
- CIK 1348911
- Filed
- May 15, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership